Nevertheless, a individual analysis from Delveinsight suggests that although Epidyolex is about to carry on dominating the marketplace and becoming a essential earner for Jazz during the in close proximity to long term, a increasing number of feasible alternative treatment plans in the uncommon epilepsies, specifically from bexicaserin and zorevune